US20040133145A1 - Device and process for extracorporeal treatment by citrate anticoagulant - Google Patents
Device and process for extracorporeal treatment by citrate anticoagulant Download PDFInfo
- Publication number
- US20040133145A1 US20040133145A1 US10/739,273 US73927303A US2004133145A1 US 20040133145 A1 US20040133145 A1 US 20040133145A1 US 73927303 A US73927303 A US 73927303A US 2004133145 A1 US2004133145 A1 US 2004133145A1
- Authority
- US
- United States
- Prior art keywords
- blood
- line
- extracorporeal circulation
- circulation according
- treating blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3424—Substitution fluid path
- A61M1/3431—Substitution fluid path upstream of the filter
- A61M1/3434—Substitution fluid path upstream of the filter with pre-dilution and post-dilution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3424—Substitution fluid path
- A61M1/3437—Substitution fluid path downstream of the filter, e.g. post-dilution with filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3455—Substitution fluids
- A61M1/3458—Substitution fluids having electrolytes not present in the dialysate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
- A61M1/3675—Deactivation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3626—Gas bubble detectors
Definitions
- the present invention relates to a device for treating blood by extracorporeal circulation, a disposable line for use in a circuit for extracorporeal circulation of blood having undergone pre-infusion of anticoagulant, and a method for anticoagulation of the blood treated by extracorporeal circulation.
- a haemodialysis session requires anticoagulation of the blood circulating in the extracorporeal circulation line in order to avoid coagulation of the blood in contact with the synthetic materials (circulation lines, dialyser fibres) .
- This anticoagulation is most often performed using heparin, which is known for its anticoagulant properties. Heparin is injected as pre-infusion into the arterial line of the device, and it is then present in the entire extracorporeal circuit of the blood, from pre-infusion until re-injection of the blood into the patient. Consequently, upon return of the blood, the patient is administered doses of heparin. Although it is necessary to prevent coagulation in the extracorporeal circulation line, in some cases the risk of the patient bleeding may pose a danger.
- FIG. 1 shows a device for treating blood by extracorporeal circulation 1 according to the prior art, comprising a filter 2 having a first chamber 3 and a second chamber 4 separated by a semi-permeable membrane 5 .
- the device comprises an arterial line 6 connected to the first chamber 3 of the filter for the circulation of blood taken from a patient 7 , and a venous line 8 issuing from the first chamber of the filter.
- a pre-infusion channel 9 is connected to a container 10 comprising a solution of heparin and is linked to the arterial line 6 , the function of the solution being to prevent coagulation of the blood outside the patient's body, and a purge channel 11 issuing from the second chamber 4 of the filter.
- An air separator 12 is linked to the venous line 8 .
- the air separator 12 also comprises an air detector 13 , and a clamp 14 is placed on the venous line 8 downstream of the air separator 12 , that is to say downstream in the direction of circulation of the blood in the venous line 8 .
- the clamp allows the flow of blood to be arrested in the event of air bubbles being detected by the detector 13 before the blood returns to the patient 7 .
- Patent application PCT/EP00/03583 concerns an infusion fluid of substitution, in particular for use in haemofiltration of blood, and an anticoagulant solution with citrate for regional anticoagulation.
- citrate ions can be used as anticoagulant.
- the citrate ions added to the blood in the extracorporeal circuit before they enter the artificial kidney, are active as anticoagulants. Thus, the risk of complications with bleeding due to systematic anticoagulation is avoided.
- some of the citrate ions pass through the artificial kidney.
- citrate ions are active as anticoagulants only in the extracorporeal circuit because, when they reach the systemic circulation of the patient, they are rapidly metabolized to bicarbonate ions.
- the subject of patent application PCT/EP00/03583 is a solution of a certain composition.
- FIG. 2 shows a device for treating blood by extracorporeal circulation 1 described in patent application PCT/EP00/03583.
- This device 1 comprises a filter 2 having a first chamber 3 and a second chamber 4 separated by a semi-permeable membrane 5 .
- the device comprises an arterial line 6 connected to the first chamber 3 of the filter for the circulation of blood taken from a patient 7 , and a venous line 8 issuing from the first chamber of the filter.
- a pre-infusion channel 9 containing an anticoagulant, trisodium citrate is connected to a container 10 comprising a solution of citrate ions and is linked to the arterial line 6 , the function of the solution being to prevent coagulation of the blood outside the patient's body.
- a purge channel 11 is linked to the outlet of the second chamber 4 of the filter, and an air separator 12 is linked on the venous line 8 .
- the venous line 8 comprises, in addition to the bubble trap 12 , a channel 13 connected to a container 14 comprising a solution for re-establishing the ionic equilibrium of the blood.
- the citrate solution renders the blood anticoagulable by decalcifying it upstream of the filter.
- This channel 13 is linked downstream of the bubble trap 12 , that is to say downstream in the direction of circulation of the blood in the venous line 8 before the blood is returned to the patient 7 .
- the teaching of this document comprises a safety device with which it is possible to detect any air bubbles present at the start of the venous line.
- the device described does not have any safety means for detecting and trapping any air bubbles in the post-infusion line linked to the venous line, and return of air to the systemic circulation of the patient, which is very dangerous for said patient, is possible.
- the structure of the bubble trap is such that on the one hand the liquid passing inside the latter is in contact with the air and the risk of coagulation is present, and, on the other hand, as the bubble trap has a greater diameter than the diameter of the venous line, the flowrate of liquid is thereby diminished and the phenomenon of coagulation thereby promoted.
- the object of the present invention is to make available a device with which it is possible to solve this problem.
- the invention provides a device for treating blood by extracorporeal circulation ( 101 ) comprising:
- a filter ( 102 ) having a first chamber ( 103 ) and a second chamber ( 104 ) separated by a semi-permeable membrane ( 105 ),
- an arterial line ( 106 ) connected to the first chamber ( 103 ) of the filter ( 102 ),
- a venous line ( 108 ) issuing from the first chamber ( 103 ) of the filter ( 102 ),
- a purge channel ( 110 ) issuing from the second chamber ( 104 ) of the filter ( 102 ),
- a line ( 112 ) for post-infusion of a solution at least partially re-establishing the ionic equilibrium of the blood downstream of the air separator ( 111 ),
- the invention also relates to a disposable venous line ( 108 ) for use in a circuit for extracorporeal circulation of blood having undergone pre-infusion of anticoagulant, comprising:
- a second channel ( 137 ) having a third connector ( 138 ) for linking to the outlet of the air separator ( 111 ) and a fourth connector ( 139 ) for linking to the blood access of a patient,
- a first part ( 141 ) of the second channel ( 137 ) connectable to an air detector ( 113 ) and placed downstream of the fifth connector ( 140 ).
- the invention also concerns a device for treating blood by extracorporeal circulation comprising said disposable venous line and according to the alternative embodiments of the disposable venous line.
- the invention relates to a method of treating blood, comprising the following steps:
- the invention also concerns a method of extracorporeal blood treatment, comprising the following steps:
- FIG. 1 shows the prior art in terms of an apparatus for extracorporeal treatment of blood with prevention of anticoagulation by heparin;
- FIG. 2 shows the prior art in terms of an apparatus for extracorporeal treatment of blood with prevention of anticoagulation by citrate
- FIG. 3 shows the device for treating blood by extracorporeal circulation according to the invention
- FIG. 4 shows a disposable line for treating blood by extracorporeal circulation according to the invention.
- FIG. 3 shows the device for extracorporeal treatment of blood according to the invention, set up to carry out dialysis treatment.
- the device for treating blood by extracorporeal circulation 101 according to the invention comprises a filter 102 having a first chamber 103 and a second chamber 104 separated by a semipermeable membrane 105 .
- the filter 105 can be a haemofilter, a plasma filter, a dialyser, or a filter of another type.
- the membranes used are hollow-fibre membranes or sheet or tube membranes.
- An arterial line 106 is connected to the first chamber 103 of the filter for circulation of blood taken from a patient 107 .
- a venous line 108 is connected to the outlet of the first chamber 103 of the filter.
- a channel 109 for pre-infusion of a substance for regional anticoagulation is linked to the arterial line 106 .
- a purge channel 110 is connected to the outlet of the second chamber 104 of the filter.
- An air separator 111 is placed on the venous line 108 and a post-infusion line 112 for a solution at least partially re-establishing the ionic equilibrium is placed downstream of the air separator 111 , that is to say downstream in the direction of circulation of the blood in the venous line 108 .
- an air detector 113 is placed downstream of the post-infusion line 112 .
- the air separator 111 can also be the only air separator present in the venous line 108 and does not contain an air detector.
- the air bubbles possibly caused by the post-infusion remain separable with a line comprising a single air separator, without bringing about undesired coagulation in the extracorporeal circuit, in particular in the air separator.
- the venous line 108 comprises a channel which can receive an occlusion means 114 downstream of the air detector.
- the occlusion means 114 comprises a clamp or a valve of another structure. In the event of air being detected, this means makes it possible to arrest the return of blood to the patient in order to eliminate the air bubbles detected.
- the post-infusion line 112 is mounted immediately upstream of the air detector 113 . Moreover the tube portion extending between the air detector and the connector to the patient is adapted not to receive any further injection device.
- the air detector operates as close as possible to the venous line connector 108 which is designed to receive a vascular access device 200 such as for instance a needle or a catheter. Indeed the air detector operates directly upstream the patient venous line conncetor 139 .
- the anticoagulant power of the pre-infusion solution is used through the greatest possible extent of the device.
- the air separator 111 comprises a bubble trap.
- the solution for regional anticoagulation contains citrate ions, for example trisodium citrate dihydrate or a solution of Anticoagulant Citrate Dextrose (ACD), comprising trisodium citrate dihydrate and citric acid monohydrate.
- citrate ions for example trisodium citrate dihydrate or a solution of Anticoagulant Citrate Dextrose (ACD), comprising trisodium citrate dihydrate and citric acid monohydrate.
- ACD Anticoagulant Citrate Dextrose
- the solution at least partially re-establishing the ionic equilibrium of the blood contains calcium ions.
- This solution can contain an isotonic solution comprising calcium chloride, potassium chloride and magnesium chloride.
- the pre-infusion line 109 is connected to the arterial line upstream of any means 115 for regulating the flow rate of liquidin the arterial line 108 .
- the pre-infusion line 109 is connected to the arterial line 106 as close as possible (immediately downstream of the patient arterial line connector 239 in reference to the patient blood flow) of the arterial line connector 239 to the patient which again is designed to receive a vascular access device 201 such as for instance a needle or a catheter.
- the arterial line 106 is operationally associated with a first means 115 of regulating the flowrate of blood.
- the pre-infusion line is operationally associated with a second means 119 of regulating the flowrate of liquid.
- the post-infusion line 112 is operationally associated with a third means 121 of regulating the flowrate of liquid.
- the purge line 110 issuing from the second chamber 104 of the filter 102 comprises a fourth means 123 of regulating the flowrate of liquid and a first means 124 of measuring the flowrate of liquid.
- a calculation and control unit (CPU) 125 is able to receive the signals emitted by a first means 124 of measuring the flowrate operating on the purge channel 110 and for controlling one or more means 115 , 119 , 121 , 123 of regulating the flowrate of liquid in order to initiate a haemofiltration operating mode.
- the device for treating blood by extracorporeal circulation 101 comprises an intake line 126 to the second chamber 104 of the filter 102 connecting up with a source 127 of dialysis liquid, for example a container of sterilized liquid or a device for preparing liquid on line.
- a source 127 of dialysis liquid for example a container of sterilized liquid or a device for preparing liquid on line.
- the citrate ions bind naturally to the calcium ions. This is why the dialysis liquid does not comprise calcium ions. This prevents reaction of the citrate contained in the pre-infusion with calcium which would be contained in the dialysis liquid. The citrate contained in the pre-infusion thus reacts solely with the calcium contained in the blood, and the anticoagulant power of the citrate is not attenuated by the dialysis liquid.
- the intake line 126 comprises a fifth means 128 of regulating the flowrate of liquid and a second means 129 of measuring the flowrate of liquid.
- a calculation and control unit (CPU) 125 is able to receive the signals emitted by one or more means 124 , 129 of measuring the flowrate of liquid and for controlling one or more means 115 , 119 , 121 , 123 , 128 of regulating the flowrate of liquid in order to initiate a haemofiltration or haemodiafiltration operating mode.
- Each means of regulating the flowrate of liquid 115 , 119 , 121 , 123 , 128 comprises a pump or a valve.
- Each means of measuring the flowrate of liquid 124 , 129 comprises a flow meter.
- a first balance 130 is provided for weighing a first reservoir 131 connected to the pre-infusion line 109 and containing the pre-infusion liquid; and a second balance 132 is provided for weighing a second reservoir 133 connected to the post-infusion line 112 and containing the post-infusion liquid.
- the calculation and control unit 125 is able to receive the signals emitted by at least one of the two balances 130 , 132 . It controls one or more means 119 , 121 of regulating the flowrate of liquid by periodically calculating the actual flowrate or a parameter which is a function of the actual flowrate.
- the quantities of anticoagulant and of solution for re-establishing the ionic equilibrium can be known and controlled during the treatment. Knowing said weights, the calculation and control unit ( 125 ) is able to directly control the means of regulating the flowrate of liquid in order to obtain a desired quantity of pre-infusion solution and/or post-infusion solution in the extracorporeal circuit.
- FIG. 4 shows the disposable venous line 108 for use in a circuit for extracorporeal circulation of blood having undergone pre-infusion of anticoagulant, said line comprising a first channel 134 having a first connector 135 for linking to a filter and a second connector 136 .
- An air separator 111 is linked to the second connector 136 downstream of the first channel 134 , that is to say downstream in the direction of the blood.
- the disposable venous line 108 also comprises a second channel 137 having a third connector 138 for linking the outlet of the air separator 111 and a fourth connector 139 for linking to the blood access of a patient.
- a fifth connector 140 is placed to connect a line 112 for post-infusion of a solution at least partially re-establishing the ionic equilibrium of the blood, the fifth connector 140 permitting fluid communication with the second channel 137 .
- the line additionally comprises a first part 141 of the second channel 137 capable of cooperating with the air detector 113 and placed downstream of the fifth connector 140 .
- the first part 141 is marked visually, for example by different colours, a relief, by a tube differentiated in terms of material, shape or size from the rest of the line.
- the post-infusion line 112 is linked to the second connector 140 in order to infuse the solution at least partially re-establishing the ionic equilibrium of the blood.
- the fifth connector 140 will be connected on the second channel 137 as close as possible to the fourth connector 139 .
- the tube portion extending between the fifth connector 140 and the fourth connector 139 is continuous and adapted not to receive any further line or any further injection device.
- the fifth connector 140 placed on the second channel 137 can be a removable connector.
- the connector 140 can comprise an end portion of the tube 112 fixed to the line 137 .
- the air separator 111 can be the only air separator present in the disposable venous line 108 .
- the air separator 111 comprises a bubble trap.
- the solution at least partially re-establishing the ionic equilibrium of the blood contains citrate ions.
- the post-infusion line 112 comprises a second part 143 connectable to a means of regulating the flowrate of the perfusion line, said second part 143 being maintained in a U-shape by means of a small bar fixing two points of the line, in order to facilitate coupling with the pump.
- the second part 143 is marked visually, for example by different colours, by a relief, by a tube differentiated in terms of material, shape or size from the rest of the line.
- the first connector 135 of the first channel 134 is either removable or fixed.
- the second connector 136 of the first channel 134 and the third connector 138 of the second channel 137 are fixed.
- the fourth connector 139 of the second channel 137 is either fixed or removable.
- the present invention affords numerous advantages.
- the air bubbles possibly introduced by the post-infusion remain detectable with a line comprising a single and unique bubble trap.
- the device thus has a simple and inexpensive structure.
- the use of said device, of said line and of said method does not entail undesired coagulation in the extracoporeal circuit, in particular in the bubble trap where the contact of air with the blood is possible and where the speed of displacement is less than in the rest of the venous line on account of the diameter of the bubble trap being larger than that of the rest of the line. This therefore results in effective prevention of administration of air to the patient.
- the anticoagulant power of the pre-infusion solution is used throughout the greatest possible extent of the device because the pre-infusion of anticoagulant is injected as far as possible upstream in the extracorporeal circuit and the post-infusion of solution re-establishing ionic equilibrium is linked as close as possible to the blood access to the patient, that is to say as far downstream as is possible on the venous line.
- This link prevents coagulation throughout the portion of line where the need for anticoagulation arises, particularly where contact between the blood and air is possible.
- the configuration of the venous line is all the more advantageous since, as a result of the location of the site of administration of the neutralizing solution, the blood, no longer comprising anticoagulant substance, at no point can come into contact with the air.
- the invention is very advantageous in cases where a device is operating for long periods, for example at a low blood flowrate in an intensive care unit, that is to say in acute treatment with a low flowrate and long duration.
- the result of anticoagulation is very advantageous because the coagulation time is increased fourfold between the perfusion of anticoagulant and the perfusion of neutralizing solution compared to the blood circulating in the rest of the circuit.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- External Artificial Organs (AREA)
Abstract
Description
- This application claims the priority of French patent application No. 02 16228, filed on Dec. 20, 2002, and the benefit of U.S. Provisional Application No. 60/453 967, filed on Mar. 13, 2003, the contents of which are incorporated herein by reference.
- The present invention relates to a device for treating blood by extracorporeal circulation, a disposable line for use in a circuit for extracorporeal circulation of blood having undergone pre-infusion of anticoagulant, and a method for anticoagulation of the blood treated by extracorporeal circulation.
- A haemodialysis session requires anticoagulation of the blood circulating in the extracorporeal circulation line in order to avoid coagulation of the blood in contact with the synthetic materials (circulation lines, dialyser fibres) . This anticoagulation is most often performed using heparin, which is known for its anticoagulant properties. Heparin is injected as pre-infusion into the arterial line of the device, and it is then present in the entire extracorporeal circuit of the blood, from pre-infusion until re-injection of the blood into the patient. Consequently, upon return of the blood, the patient is administered doses of heparin. Although it is necessary to prevent coagulation in the extracorporeal circulation line, in some cases the risk of the patient bleeding may pose a danger. This is particularly true of patients at high risk of haemorrhaging (for example in the days following major surgery) or in those patients with hypersensitivity to heparin. Consequently, anti-coagulation with heparin may prove dangerous to the patient on account of heparin being injected via the return of blood to the patient.
- FIG. 1 shows a device for treating blood by extracorporeal circulation1 according to the prior art, comprising a
filter 2 having afirst chamber 3 and asecond chamber 4 separated by asemi-permeable membrane 5. The device comprises anarterial line 6 connected to thefirst chamber 3 of the filter for the circulation of blood taken from apatient 7, and avenous line 8 issuing from the first chamber of the filter. Apre-infusion channel 9 is connected to acontainer 10 comprising a solution of heparin and is linked to thearterial line 6, the function of the solution being to prevent coagulation of the blood outside the patient's body, and apurge channel 11 issuing from thesecond chamber 4 of the filter. Anair separator 12 is linked to thevenous line 8. Theair separator 12 also comprises anair detector 13, and aclamp 14 is placed on thevenous line 8 downstream of theair separator 12, that is to say downstream in the direction of circulation of the blood in thevenous line 8. The clamp allows the flow of blood to be arrested in the event of air bubbles being detected by thedetector 13 before the blood returns to thepatient 7. - Thus, as was mentioned above, the solution of heparin acts against coagulation of the blood throughout the device1 and also in the patient's body. Consequently, the return and injection of heparin into the body of the
patient 7 can prove dangerous. - Patent application PCT/EP00/03583 concerns an infusion fluid of substitution, in particular for use in haemofiltration of blood, and an anticoagulant solution with citrate for regional anticoagulation. In order to avoid coagulation of blood during a haemodialysis session, it is known that citrate ions can be used as anticoagulant. The citrate ions, added to the blood in the extracorporeal circuit before they enter the artificial kidney, are active as anticoagulants. Thus, the risk of complications with bleeding due to systematic anticoagulation is avoided. During the haemofiltration, some of the citrate ions pass through the artificial kidney. The citrate ions are active as anticoagulants only in the extracorporeal circuit because, when they reach the systemic circulation of the patient, they are rapidly metabolized to bicarbonate ions. The subject of patent application PCT/EP00/03583 is a solution of a certain composition.
- FIG. 2 shows a device for treating blood by extracorporeal circulation1 described in patent application PCT/EP00/03583. This device 1 comprises a
filter 2 having afirst chamber 3 and asecond chamber 4 separated by asemi-permeable membrane 5. The device comprises anarterial line 6 connected to thefirst chamber 3 of the filter for the circulation of blood taken from apatient 7, and avenous line 8 issuing from the first chamber of the filter. Apre-infusion channel 9 containing an anticoagulant, trisodium citrate, is connected to acontainer 10 comprising a solution of citrate ions and is linked to thearterial line 6, the function of the solution being to prevent coagulation of the blood outside the patient's body. Apurge channel 11 is linked to the outlet of thesecond chamber 4 of the filter, and anair separator 12 is linked on thevenous line 8. - The
venous line 8 comprises, in addition to thebubble trap 12, achannel 13 connected to acontainer 14 comprising a solution for re-establishing the ionic equilibrium of the blood. The citrate solution renders the blood anticoagulable by decalcifying it upstream of the filter. Thischannel 13 is linked downstream of thebubble trap 12, that is to say downstream in the direction of circulation of the blood in thevenous line 8 before the blood is returned to thepatient 7. - The reason is that, in order to re-establish correct haemostasis, the ionic equilibrium of the blood must be re-established, specifically by recalcifying it, after leaving the filter.
- The teaching of this document comprises a safety device with which it is possible to detect any air bubbles present at the start of the venous line. By contrast, the device described does not have any safety means for detecting and trapping any air bubbles in the post-infusion line linked to the venous line, and return of air to the systemic circulation of the patient, which is very dangerous for said patient, is possible.
- In seeking to solve this problem, the persons skilled in the art have tried linking the post-infusion line, containing an infusion solution of substitution, directly to the bubble trap of the venous line and not downstream thereof. Moreover, the bubble detector has been placed on this bubble trap. In this way, a single device makes it possible simultaneously to separate and detect the air bubbles coming from, on the one hand, the blood liquid extracted from the filter and, on the other hand, coming from the post-infusion liquid.
- However, in trials carried out with this set-up, it has been found, especially in prolonged operation, for example with slow blood flowrates in an intensive care unit, that although the problem of air bubbles in the two liquids is solved, a new problem arises: namely that of coagulation within the bubble trap. This is because the blood liquid extracted from the filter and arriving in the bubble trap comprises an anticoagulant liquid which has been injected in pre-infusion into the patient's blood during its passage through the arterial line. Moreover, the bubble trap also receives an infusion solution of substitution, whose effect is to neutralize the anticoagulant effect of the pre-infusion solution. The structure of the bubble trap is such that on the one hand the liquid passing inside the latter is in contact with the air and the risk of coagulation is present, and, on the other hand, as the bubble trap has a greater diameter than the diameter of the venous line, the flowrate of liquid is thereby diminished and the phenomenon of coagulation thereby promoted.
- It is also known in U.S. Pat. No. 5,330,425 (Utterberg) a device concerning the injection in the venous line of drugs and the like. It is also known an haemodialysis machine having an air-detector/line clamp assembly mounted on the venous line typically at least two inches below a venous chamber, in which it is possible to design a venous bloodline wherein an injection site is placed in the tubing downstream of the venous chamber, yet upstream of the air-detector/line clamp.
- Another prior art is the patent U.S. Pat. No. 4,490,135 (Troutner) which discloses a single needle haemodialysis system having two air detectors on the venous line.
- There is therefore the twin problem of detecting the bubbles in each of the two liquids using-a device of simple structure, and of preventing coagulation of the blood throughout the extracorporeal circuit.
- The object of the present invention is to make available a device with which it is possible to solve this problem.
- To achieve this object, the invention provides a device for treating blood by extracorporeal circulation (101) comprising:
- a filter (102) having a first chamber (103) and a second chamber (104) separated by a semi-permeable membrane (105),
- an arterial line (106) connected to the first chamber (103) of the filter (102),
- a venous line (108) issuing from the first chamber (103) of the filter (102),
- a channel (109) used for pre-infusion of a substance for regional anticoagulation and linked to the arterial line (106),
- a purge channel (110) issuing from the second chamber (104) of the filter (102),
- an air separator (112) on the venous line (108),
- a line (112) for post-infusion of a solution at least partially re-establishing the ionic equilibrium of the blood downstream of the air separator (111),
- an air detector (113) downstream of the post-infusion line (112).
- The invention also relates to a disposable venous line (108) for use in a circuit for extracorporeal circulation of blood having undergone pre-infusion of anticoagulant, comprising:
- a first channel (134) having a first connector (135) for linking to a filter and a second connector (136),
- an air separator (111) linked to the second connector (136) downstream of the first channel (134),
- a second channel (137) having a third connector (138) for linking to the outlet of the air separator (111) and a fourth connector (139) for linking to the blood access of a patient,
- a fifth connector (140) for linking a line (112) for post-infusion of a solution at least partially re-establishing the ionic equilibrium of the blood, the fifth connector permitting fluid communication with the second channel (137),
- a first part (141) of the second channel (137) connectable to an air detector (113) and placed downstream of the fifth connector (140).
- The invention also concerns a device for treating blood by extracorporeal circulation comprising said disposable venous line and according to the alternative embodiments of the disposable venous line.
- Finally, the invention relates to a method of treating blood, comprising the following steps:
- infusing a substance for regional anti-coagulation into what is called an arterial line carrying blood which has been taken beforehand from a patient,
- passing the extracted blood through a filter,
- after passage of the blood through the filter, eliminating the possible presence of air in the blood circulating in what is called a venous line,
- after possible elimination of the air, infusing a solution at least partially re-establishing the ionic equilibrium of the blood,
- after infusion of solution to re-establish the ionic equilibrium, detecting the possible presence of air,
- in the event of air being detected, clamping what is called the venous line downstream of the post-infusion, without passing through a second air separator placed downstream of the first air separator.
- The invention also concerns a method of extracorporeal blood treatment, comprising the following steps:
- extracting blood from a patient at a given flowrate,
- infusing a substance for regional anti-coagulation into the extracted blood,
- passing the extracted blood through a filter,
- after passage of the blood through the filter, eliminating the possible presence of air in the blood passing through a venous line,
- after possible elimination of air, infusing a solution at least partially re-establishing the ionic equilibrium of the blood,
- after infusion of solution to re-establish the ionic equilibrium, detecting the possible presence of air,
- in the event of air being detected, clamping the venous line downstream of the post-infusion,
- returning the blood to the patient, without passing through a second air separator placed downstream of the first air separator.
- Other advantages and characteristics of the invention will become evident from reading the description which follows.
- Reference will be made to the attached drawings, in which:
- FIG. 1 shows the prior art in terms of an apparatus for extracorporeal treatment of blood with prevention of anticoagulation by heparin;
- FIG. 2 shows the prior art in terms of an apparatus for extracorporeal treatment of blood with prevention of anticoagulation by citrate;
- FIG. 3 shows the device for treating blood by extracorporeal circulation according to the invention;
- FIG. 4 shows a disposable line for treating blood by extracorporeal circulation according to the invention.
- FIG. 3 shows the device for extracorporeal treatment of blood according to the invention, set up to carry out dialysis treatment. The device for treating blood by extracorporeal circulation101 according to the invention comprises a
filter 102 having afirst chamber 103 and asecond chamber 104 separated by asemipermeable membrane 105. Depending on the membrane, thefilter 105 can be a haemofilter, a plasma filter, a dialyser, or a filter of another type. As regards the membrane, the membranes used are hollow-fibre membranes or sheet or tube membranes. Anarterial line 106 is connected to thefirst chamber 103 of the filter for circulation of blood taken from apatient 107. Avenous line 108 is connected to the outlet of thefirst chamber 103 of the filter. Achannel 109 for pre-infusion of a substance for regional anticoagulation is linked to thearterial line 106. Apurge channel 110 is connected to the outlet of thesecond chamber 104 of the filter. Anair separator 111 is placed on thevenous line 108 and apost-infusion line 112 for a solution at least partially re-establishing the ionic equilibrium is placed downstream of theair separator 111, that is to say downstream in the direction of circulation of the blood in thevenous line 108. Finally, anair detector 113 is placed downstream of thepost-infusion line 112. - No other air separator is inserted downstream of the
air detector 113. Theair separator 111 can also be the only air separator present in thevenous line 108 and does not contain an air detector. - In this way, the air bubbles possibly caused by the post-infusion remain separable with a line comprising a single air separator, without bringing about undesired coagulation in the extracorporeal circuit, in particular in the air separator.
- The
venous line 108 comprises a channel which can receive an occlusion means 114 downstream of the air detector. The occlusion means 114 comprises a clamp or a valve of another structure. In the event of air being detected, this means makes it possible to arrest the return of blood to the patient in order to eliminate the air bubbles detected. - The
post-infusion line 112 is mounted immediately upstream of theair detector 113. Moreover the tube portion extending between the air detector and the connector to the patient is adapted not to receive any further injection device. The air detector operates as close as possible to thevenous line connector 108 which is designed to receive avascular access device 200 such as for instance a needle or a catheter. Indeed the air detector operates directly upstream the patientvenous line conncetor 139. - Thus, the anticoagulant power of the pre-infusion solution is used through the greatest possible extent of the device.
- The
air separator 111 comprises a bubble trap. The solution for regional anticoagulation contains citrate ions, for example trisodium citrate dihydrate or a solution of Anticoagulant Citrate Dextrose (ACD), comprising trisodium citrate dihydrate and citric acid monohydrate. - The solution at least partially re-establishing the ionic equilibrium of the blood contains calcium ions. This solution can contain an isotonic solution comprising calcium chloride, potassium chloride and magnesium chloride.
- Referring again to the sense of blood flow within the arterial line, the
pre-infusion line 109 is connected to the arterial line upstream of anymeans 115 for regulating the flow rate of liquidin thearterial line 108. According to one embodiment thepre-infusion line 109 is connected to thearterial line 106 as close as possible (immediately downstream of the patientarterial line connector 239 in reference to the patient blood flow) of thearterial line connector 239 to the patient which again is designed to receive avascular access device 201 such as for instance a needle or a catheter. - In this way, the anticoagulation power of the pre-infusion solution is immediately available as soon as patient blood enters into the extracorporeal circuit.
- The
arterial line 106 is operationally associated with a first means 115 of regulating the flowrate of blood. - The pre-infusion line is operationally associated with a second means119 of regulating the flowrate of liquid.
- The
post-infusion line 112 is operationally associated with a third means 121 of regulating the flowrate of liquid. - The
purge line 110 issuing from thesecond chamber 104 of thefilter 102 comprises a fourth means 123 of regulating the flowrate of liquid and a first means 124 of measuring the flowrate of liquid. - A calculation and control unit (CPU)125 is able to receive the signals emitted by a first means 124 of measuring the flowrate operating on the
purge channel 110 and for controlling one or more means 115, 119, 121, 123 of regulating the flowrate of liquid in order to initiate a haemofiltration operating mode. - The device for treating blood by extracorporeal circulation101 comprises an
intake line 126 to thesecond chamber 104 of thefilter 102 connecting up with asource 127 of dialysis liquid, for example a container of sterilized liquid or a device for preparing liquid on line. - The citrate ions bind naturally to the calcium ions. This is why the dialysis liquid does not comprise calcium ions. This prevents reaction of the citrate contained in the pre-infusion with calcium which would be contained in the dialysis liquid. The citrate contained in the pre-infusion thus reacts solely with the calcium contained in the blood, and the anticoagulant power of the citrate is not attenuated by the dialysis liquid.
- The
intake line 126 comprises a fifth means 128 of regulating the flowrate of liquid and a second means 129 of measuring the flowrate of liquid. - A calculation and control unit (CPU)125 is able to receive the signals emitted by one or more means 124, 129 of measuring the flowrate of liquid and for controlling one or more means 115, 119, 121, 123, 128 of regulating the flowrate of liquid in order to initiate a haemofiltration or haemodiafiltration operating mode.
- Each means of regulating the flowrate of
liquid liquid - A
first balance 130 is provided for weighing afirst reservoir 131 connected to thepre-infusion line 109 and containing the pre-infusion liquid; and asecond balance 132 is provided for weighing asecond reservoir 133 connected to thepost-infusion line 112 and containing the post-infusion liquid. - The calculation and
control unit 125 is able to receive the signals emitted by at least one of the twobalances - Thus, the quantities of anticoagulant and of solution for re-establishing the ionic equilibrium can be known and controlled during the treatment. Knowing said weights, the calculation and control unit (125) is able to directly control the means of regulating the flowrate of liquid in order to obtain a desired quantity of pre-infusion solution and/or post-infusion solution in the extracorporeal circuit.
- FIG. 4 shows the disposable
venous line 108 for use in a circuit for extracorporeal circulation of blood having undergone pre-infusion of anticoagulant, said line comprising afirst channel 134 having afirst connector 135 for linking to a filter and asecond connector 136. Anair separator 111 is linked to thesecond connector 136 downstream of thefirst channel 134, that is to say downstream in the direction of the blood. The disposablevenous line 108 also comprises asecond channel 137 having athird connector 138 for linking the outlet of theair separator 111 and afourth connector 139 for linking to the blood access of a patient. Afifth connector 140 is placed to connect aline 112 for post-infusion of a solution at least partially re-establishing the ionic equilibrium of the blood, thefifth connector 140 permitting fluid communication with thesecond channel 137. The line additionally comprises afirst part 141 of thesecond channel 137 capable of cooperating with theair detector 113 and placed downstream of thefifth connector 140. - The
first part 141 is marked visually, for example by different colours, a relief, by a tube differentiated in terms of material, shape or size from the rest of the line. - The
post-infusion line 112 is linked to thesecond connector 140 in order to infuse the solution at least partially re-establishing the ionic equilibrium of the blood. - The
fifth connector 140 will be connected on thesecond channel 137 as close as possible to thefourth connector 139. - The tube portion extending between the
fifth connector 140 and thefourth connector 139 is continuous and adapted not to receive any further line or any further injection device. - The
fifth connector 140 placed on thesecond channel 137 can be a removable connector. Alternatively, theconnector 140 can comprise an end portion of thetube 112 fixed to theline 137. - No other air separator is inserted downstream of the
first part 141 of thesecond channel 137 connectable to theair detector 113. - The
air separator 111 can be the only air separator present in the disposablevenous line 108. - The
air separator 111 comprises a bubble trap. - The solution at least partially re-establishing the ionic equilibrium of the blood contains citrate ions.
- The
post-infusion line 112 comprises asecond part 143 connectable to a means of regulating the flowrate of the perfusion line, saidsecond part 143 being maintained in a U-shape by means of a small bar fixing two points of the line, in order to facilitate coupling with the pump. - The
second part 143 is marked visually, for example by different colours, by a relief, by a tube differentiated in terms of material, shape or size from the rest of the line. - The
first connector 135 of thefirst channel 134 is either removable or fixed. - The
second connector 136 of thefirst channel 134 and thethird connector 138 of thesecond channel 137 are fixed. - The
fourth connector 139 of thesecond channel 137 is either fixed or removable. - The present invention affords numerous advantages. The air bubbles possibly introduced by the post-infusion remain detectable with a line comprising a single and unique bubble trap. The device thus has a simple and inexpensive structure.
- Moreover, the use of said device, of said line and of said method does not entail undesired coagulation in the extracoporeal circuit, in particular in the bubble trap where the contact of air with the blood is possible and where the speed of displacement is less than in the rest of the venous line on account of the diameter of the bubble trap being larger than that of the rest of the line. This therefore results in effective prevention of administration of air to the patient.
- Thus, the anticoagulant power of the pre-infusion solution is used throughout the greatest possible extent of the device because the pre-infusion of anticoagulant is injected as far as possible upstream in the extracorporeal circuit and the post-infusion of solution re-establishing ionic equilibrium is linked as close as possible to the blood access to the patient, that is to say as far downstream as is possible on the venous line. This link prevents coagulation throughout the portion of line where the need for anticoagulation arises, particularly where contact between the blood and air is possible. The configuration of the venous line is all the more advantageous since, as a result of the location of the site of administration of the neutralizing solution, the blood, no longer comprising anticoagulant substance, at no point can come into contact with the air.
- In addition, the invention is very advantageous in cases where a device is operating for long periods, for example at a low blood flowrate in an intensive care unit, that is to say in acute treatment with a low flowrate and long duration.
- It has been confirmed that the dialysis values measured during extracorporeal treatment according to the invention remain as stable as with an anticoagulant of the heparin type re-injected into the patient.
- Thus, the result of anticoagulation is very advantageous because the coagulation time is increased fourfold between the perfusion of anticoagulant and the perfusion of neutralizing solution compared to the blood circulating in the rest of the circuit.
- Finally, at the end of the session, the compression time needed for haemostasis of the fistula is reduced compared to treatment with administration of heparin because the blood re-injected into the patient has recovered its normal coagulating power.
Claims (31)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/739,273 US7351218B2 (en) | 2002-12-20 | 2003-12-19 | Device and process for extracorporeal treatment by citrate anticoagulant |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0216228A FR2848857B1 (en) | 2002-12-20 | 2002-12-20 | SINGLE-USE DEVICE AND LINE FOR THE EXTRACORPOREAL TREATMENT OF BLOOD BY CITRATE ANTICOAGULATION |
FR0216228 | 2002-12-20 | ||
US45396703P | 2003-03-13 | 2003-03-13 | |
US10/739,273 US7351218B2 (en) | 2002-12-20 | 2003-12-19 | Device and process for extracorporeal treatment by citrate anticoagulant |
Publications (2)
Publication Number | Publication Date |
---|---|
US20040133145A1 true US20040133145A1 (en) | 2004-07-08 |
US7351218B2 US7351218B2 (en) | 2008-04-01 |
Family
ID=32685742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/739,273 Active 2024-12-27 US7351218B2 (en) | 2002-12-20 | 2003-12-19 | Device and process for extracorporeal treatment by citrate anticoagulant |
Country Status (1)
Country | Link |
---|---|
US (1) | US7351218B2 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050101901A1 (en) * | 2001-11-16 | 2005-05-12 | Victor Gura | Wearable continuous renal replacement therapy device |
US20050143684A1 (en) * | 2000-11-03 | 2005-06-30 | Charles Bolan | Apheresis methods and devices |
US20070038191A1 (en) * | 2003-01-15 | 2007-02-15 | Burbank Jeffrey H | Waste balancing for extracorporeal blood treatment systems |
US20070066928A1 (en) * | 2005-09-22 | 2007-03-22 | Jean-Michel Lannoy | Automation and optimization of CRRT treatment using regional citrate anticoagulation |
WO2007101064A2 (en) * | 2006-02-22 | 2007-09-07 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
US20080015487A1 (en) * | 2006-02-22 | 2008-01-17 | Henry Ford Health System | System and Method for Delivery of Regional Citrate Anticoagulation to Extracorporeal Blood Circuits |
US20100022936A1 (en) * | 2001-11-16 | 2010-01-28 | National Quality Care, Inc. | Wearable ultrafiltration device |
US20100094193A1 (en) * | 2001-11-16 | 2010-04-15 | National Quality Care, Inc. | Wearable ultrafiltration device |
US20110142700A1 (en) * | 2001-11-16 | 2011-06-16 | Fresenius Medical Care Holdings, Inc. | Dual-ventricle pump cartridge, pump, and method of use in a wearable continuous renal replacement therapy device |
JP2012135499A (en) * | 2010-12-27 | 2012-07-19 | Asahi Kasei Medical Co Ltd | Blood purification system |
US8235931B2 (en) | 2003-01-15 | 2012-08-07 | Nxstage Medical, Inc. | Waste balancing for extracorporeal blood treatment systems |
AT505690B1 (en) * | 2007-08-31 | 2012-09-15 | Zentrum Fuer Biomedizinische Technologie Der Donau Uni Krems | METHOD OF DETERMINING ION CONCENTRATION IN CITRATE ANTICOAGULATED EXTRACORPORAL BLOOD CLEANING |
EP2526981A1 (en) * | 2011-05-25 | 2012-11-28 | Bellco S.r.l. | Infusion assembly of a dialysis machine |
EP2653178A1 (en) | 2012-04-16 | 2013-10-23 | Zentrum für biomedizinische Technologie der Donau- Universität Krems | Safety device for extracorporeal blood treatment |
KR20140137443A (en) * | 2012-03-21 | 2014-12-02 | 감브로 룬디아 아베 | Treatment solution delivery in an extracorporeal blood treatment apparatus |
US20140353251A1 (en) * | 2009-06-17 | 2014-12-04 | Fresenius Medical Care Holdings, Inc. | Methods of Regional Citrate Anticoagulation Dialysis |
US20160121035A1 (en) * | 2014-10-31 | 2016-05-05 | B. Braun Avitum Ag | System and method for flexible citrate anticoagulation during extracorporeal blood treatment using feed-forward control |
EP2324871B1 (en) | 2005-11-22 | 2016-06-22 | Nikkiso Co., Ltd. | Citrate anticoagulation system for extracorporeal blood treatments |
EP3042673A1 (en) * | 2007-09-05 | 2016-07-13 | Gambro Lundia AB | Infusion site for improved mixing of fluids |
US10695482B2 (en) | 2011-10-14 | 2020-06-30 | Seastar Medical, Inc. | Cartridge and method for increasing myocardial function |
US11118162B2 (en) | 2010-10-15 | 2021-09-14 | Seastar Medical, Inc. | Cytopheresis cartridges and use thereof |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060076295A1 (en) | 2004-03-15 | 2006-04-13 | The Trustees Of Columbia University In The City Of New York | Systems and methods of blood-based therapies having a microfluidic membraneless exchange device |
JP4489761B2 (en) * | 2003-03-14 | 2010-06-23 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | System and method for blood-based therapy with a microfluidic membraneless device |
US7713226B2 (en) * | 2006-01-06 | 2010-05-11 | Renal Solutions, Inc. | On demand and post-treatment delivery of saline to a dialysis patient |
WO2007137245A2 (en) | 2006-05-22 | 2007-11-29 | Columbia University | Systems and methods of microfluidic membraneless exchange using filtration of extraction fluid outlet streams |
SE534780C2 (en) * | 2006-11-17 | 2011-12-20 | Fresenius Med Care Hldg Inc | Purification in an artificial kidney containing a pulsatory pump |
KR20100061704A (en) * | 2007-08-31 | 2010-06-08 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Selective cytopheresis devices and related methods thereof |
US8597505B2 (en) | 2007-09-13 | 2013-12-03 | Fresenius Medical Care Holdings, Inc. | Portable dialysis machine |
US20090114037A1 (en) * | 2007-10-11 | 2009-05-07 | Mark Forrest Smith | Photo-Acoustic Flow Meter |
US9358331B2 (en) | 2007-09-13 | 2016-06-07 | Fresenius Medical Care Holdings, Inc. | Portable dialysis machine with improved reservoir heating system |
US8240636B2 (en) | 2009-01-12 | 2012-08-14 | Fresenius Medical Care Holdings, Inc. | Valve system |
US20090101577A1 (en) * | 2007-09-28 | 2009-04-23 | Fulkerson Barry N | Methods and Systems for Controlling Ultrafiltration Using Central Venous Pressure Measurements |
US8105487B2 (en) | 2007-09-25 | 2012-01-31 | Fresenius Medical Care Holdings, Inc. | Manifolds for use in conducting dialysis |
US9308307B2 (en) | 2007-09-13 | 2016-04-12 | Fresenius Medical Care Holdings, Inc. | Manifold diaphragms |
US8114288B2 (en) | 2007-11-29 | 2012-02-14 | Fresenlus Medical Care Holdings, Inc. | System and method for conducting hemodialysis and hemofiltration |
US9199022B2 (en) | 2008-09-12 | 2015-12-01 | Fresenius Medical Care Holdings, Inc. | Modular reservoir assembly for a hemodialysis and hemofiltration system |
US8475399B2 (en) * | 2009-02-26 | 2013-07-02 | Fresenius Medical Care Holdings, Inc. | Methods and systems for measuring and verifying additives for use in a dialysis machine |
ES2542999T5 (en) * | 2007-10-24 | 2024-02-23 | Nikkiso Co Ltd | Optimizing clearance for protein-bound molecules using cascade filtration therapy |
AU2009212396A1 (en) * | 2008-02-04 | 2009-08-13 | The Trustees Of Columbia University In The City Of New York | Fluid separation devices, systems and methods |
WO2010042667A2 (en) * | 2008-10-07 | 2010-04-15 | Xcorporeal, Inc. | Thermal flow meter |
CA2976872C (en) | 2008-10-07 | 2021-04-13 | Fresenius Medical Care Holdings, Inc. | Priming system and method for dialysis systems |
CN105056324B (en) | 2008-10-30 | 2019-01-01 | 弗雷塞尼斯医疗保健控股公司 | Modular portable dialysis system |
WO2010112538A1 (en) | 2009-03-31 | 2010-10-07 | Gambro Lundia Ab | A multipart fluid system and a system for regional citrate anticoagulation in an extracorporeal blood circuit |
ES2887240T3 (en) | 2011-08-30 | 2021-12-22 | Gambro Lundia Ab | Apparatus for extracorporeal blood treatment |
US9201036B2 (en) | 2012-12-21 | 2015-12-01 | Fresenius Medical Care Holdings, Inc. | Method and system of monitoring electrolyte levels and composition using capacitance or induction |
US9157786B2 (en) | 2012-12-24 | 2015-10-13 | Fresenius Medical Care Holdings, Inc. | Load suspension and weighing system for a dialysis machine reservoir |
US9354640B2 (en) | 2013-11-11 | 2016-05-31 | Fresenius Medical Care Holdings, Inc. | Smart actuator for valve |
EP3386561B1 (en) | 2015-12-11 | 2023-05-03 | NxStage Medical, Inc. | Fluid line connector devices methods and systems |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3946731A (en) * | 1971-01-20 | 1976-03-30 | Lichtenstein Eric Stefan | Apparatus for extracorporeal treatment of blood |
US4464164A (en) * | 1982-09-24 | 1984-08-07 | Extracorporeal Medical Specialties, Inc. | Flowrate control for a blood flow system |
US4490135A (en) * | 1982-09-24 | 1984-12-25 | Extracorporeal Medical Specialties, Inc. | Single needle alternating blood flow system |
US4500309A (en) * | 1982-05-07 | 1985-02-19 | The Kansas University Endowment Association | Method for regional anticoagulation during extracorporeal dialysis |
US4571244A (en) * | 1984-05-07 | 1986-02-18 | Biogenesis, Inc. | System for removing gas bubbles from liquids |
US4894150A (en) * | 1982-04-10 | 1990-01-16 | Schurek Hans Joachim | Mechanical device for simplifying fluid balance in hemofiltration |
US5032615A (en) * | 1989-10-31 | 1991-07-16 | The Regents Of The University Of California | Continuous hemodialysis using citrate |
US5205153A (en) * | 1992-01-23 | 1993-04-27 | Cobe Laboratories, Inc. | Method and apparatus for detection of air bubbles in tubing |
US5330425A (en) * | 1992-04-30 | 1994-07-19 | Utterberg David S | Blow molded venous drip chamber for hemodialysis |
US5344568A (en) * | 1991-10-11 | 1994-09-06 | Children's Hospital Medical Center | Hemofiltration system and method |
US5470483A (en) * | 1993-03-22 | 1995-11-28 | Hospal Industrie | Device and method for controlling the balance of fluids in an extracorporeal blood circuit |
US5529685A (en) * | 1992-07-07 | 1996-06-25 | Senko Medical Instrument Mfg. Co., Ltd. | Dialysis system for returning blood in the system after the completion of dialysis |
US5578223A (en) * | 1991-09-10 | 1996-11-26 | Hospal Industrie | Artificial kidney and method for adjusting a concentration of substance in blood using thereof |
US5650071A (en) * | 1995-06-07 | 1997-07-22 | Cobe Laboratories, Inc. | Technique for priming and recirculating fluid through a dialysis machine to prepare the machine for use |
US5676841A (en) * | 1991-12-23 | 1997-10-14 | Baxter International Inc. | Blood processing systems and methods which monitor citrate return to the donor |
US5762805A (en) * | 1993-02-12 | 1998-06-09 | Cobe Laboratories, Inc. | Technique for extracorporeal treatment of blood |
US6123847A (en) * | 1997-08-21 | 2000-09-26 | Hospal Industrie | Device and process for regulating the sodium concentration in a dialysis liquid with a view to a prescription |
US20020004530A1 (en) * | 2000-05-24 | 2002-01-10 | Warnock David G. | Use of citrate-containing dialysate for renal dialysis treatment |
US6454736B1 (en) * | 1998-05-29 | 2002-09-24 | Fresenius Ag | Method of filling a tube system with a rinsing liquid and a tube system for use with this method |
US20030045827A1 (en) * | 2000-12-22 | 2003-03-06 | Volker Nier | Method for determining concentration; a dialyser |
US6561997B1 (en) * | 1999-04-23 | 2003-05-13 | The Regents Of The University Of Michigan | Extracorporeal fluid circuit and related methods |
US6572576B2 (en) * | 2001-07-07 | 2003-06-03 | Nxstage Medical, Inc. | Method and apparatus for leak detection in a fluid line |
US6726647B1 (en) * | 1998-10-23 | 2004-04-27 | Gambro Ab | Method and device for measuring access flow |
US6743191B1 (en) * | 1999-04-26 | 2004-06-01 | Edwards Lifesciences Ag | Substitution infusion fluid and citrate anticoagulation |
US7029456B2 (en) * | 2003-10-15 | 2006-04-18 | Baxter International Inc. | Medical fluid therapy flow balancing and synchronization system |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1223322B (en) | 1987-10-23 | 1990-09-19 | Crinos Industria Farmaco | METHOD FOR PREVENTING THE FORMATION OF BLOOD CLOTS IN THE EXTRA-BODY CIRCUIT OF DIALYSIS EQUIPMENT USEFUL FOR IT |
DE4230513C1 (en) | 1992-09-11 | 1994-03-31 | Fresenius Ag | Device for removing aluminum ions from blood and solution for use in the device |
-
2003
- 2003-12-19 US US10/739,273 patent/US7351218B2/en active Active
Patent Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3946731A (en) * | 1971-01-20 | 1976-03-30 | Lichtenstein Eric Stefan | Apparatus for extracorporeal treatment of blood |
US4894150A (en) * | 1982-04-10 | 1990-01-16 | Schurek Hans Joachim | Mechanical device for simplifying fluid balance in hemofiltration |
US4500309A (en) * | 1982-05-07 | 1985-02-19 | The Kansas University Endowment Association | Method for regional anticoagulation during extracorporeal dialysis |
US4464164A (en) * | 1982-09-24 | 1984-08-07 | Extracorporeal Medical Specialties, Inc. | Flowrate control for a blood flow system |
US4490135A (en) * | 1982-09-24 | 1984-12-25 | Extracorporeal Medical Specialties, Inc. | Single needle alternating blood flow system |
US4571244A (en) * | 1984-05-07 | 1986-02-18 | Biogenesis, Inc. | System for removing gas bubbles from liquids |
US5032615A (en) * | 1989-10-31 | 1991-07-16 | The Regents Of The University Of California | Continuous hemodialysis using citrate |
US5578223A (en) * | 1991-09-10 | 1996-11-26 | Hospal Industrie | Artificial kidney and method for adjusting a concentration of substance in blood using thereof |
US5344568A (en) * | 1991-10-11 | 1994-09-06 | Children's Hospital Medical Center | Hemofiltration system and method |
US5344568B1 (en) * | 1991-10-11 | 1999-09-07 | Childrens Hosp Medical Center | Hemofiltration system and method |
US5676841A (en) * | 1991-12-23 | 1997-10-14 | Baxter International Inc. | Blood processing systems and methods which monitor citrate return to the donor |
US5205153A (en) * | 1992-01-23 | 1993-04-27 | Cobe Laboratories, Inc. | Method and apparatus for detection of air bubbles in tubing |
US5330425A (en) * | 1992-04-30 | 1994-07-19 | Utterberg David S | Blow molded venous drip chamber for hemodialysis |
US5529685A (en) * | 1992-07-07 | 1996-06-25 | Senko Medical Instrument Mfg. Co., Ltd. | Dialysis system for returning blood in the system after the completion of dialysis |
US5762805A (en) * | 1993-02-12 | 1998-06-09 | Cobe Laboratories, Inc. | Technique for extracorporeal treatment of blood |
US5470483A (en) * | 1993-03-22 | 1995-11-28 | Hospal Industrie | Device and method for controlling the balance of fluids in an extracorporeal blood circuit |
US5650071A (en) * | 1995-06-07 | 1997-07-22 | Cobe Laboratories, Inc. | Technique for priming and recirculating fluid through a dialysis machine to prepare the machine for use |
US6123847A (en) * | 1997-08-21 | 2000-09-26 | Hospal Industrie | Device and process for regulating the sodium concentration in a dialysis liquid with a view to a prescription |
US6454736B1 (en) * | 1998-05-29 | 2002-09-24 | Fresenius Ag | Method of filling a tube system with a rinsing liquid and a tube system for use with this method |
US6726647B1 (en) * | 1998-10-23 | 2004-04-27 | Gambro Ab | Method and device for measuring access flow |
US6561997B1 (en) * | 1999-04-23 | 2003-05-13 | The Regents Of The University Of Michigan | Extracorporeal fluid circuit and related methods |
US6743191B1 (en) * | 1999-04-26 | 2004-06-01 | Edwards Lifesciences Ag | Substitution infusion fluid and citrate anticoagulation |
US20020004530A1 (en) * | 2000-05-24 | 2002-01-10 | Warnock David G. | Use of citrate-containing dialysate for renal dialysis treatment |
US20030045827A1 (en) * | 2000-12-22 | 2003-03-06 | Volker Nier | Method for determining concentration; a dialyser |
US6572576B2 (en) * | 2001-07-07 | 2003-06-03 | Nxstage Medical, Inc. | Method and apparatus for leak detection in a fluid line |
US7029456B2 (en) * | 2003-10-15 | 2006-04-18 | Baxter International Inc. | Medical fluid therapy flow balancing and synchronization system |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050143684A1 (en) * | 2000-11-03 | 2005-06-30 | Charles Bolan | Apheresis methods and devices |
US8137299B2 (en) | 2001-11-16 | 2012-03-20 | Fresenius Medical Care Holdings, Inc. | Wearable ultrafiltration device |
US20050101901A1 (en) * | 2001-11-16 | 2005-05-12 | Victor Gura | Wearable continuous renal replacement therapy device |
US20100022936A1 (en) * | 2001-11-16 | 2010-01-28 | National Quality Care, Inc. | Wearable ultrafiltration device |
US8206331B2 (en) | 2001-11-16 | 2012-06-26 | Fresenius Medical Care Holdings, Inc. | Wearable ultrafiltration device |
US20110142700A1 (en) * | 2001-11-16 | 2011-06-16 | Fresenius Medical Care Holdings, Inc. | Dual-ventricle pump cartridge, pump, and method of use in a wearable continuous renal replacement therapy device |
US7309323B2 (en) * | 2001-11-16 | 2007-12-18 | National Quality Care, Inc. | Wearable continuous renal replacement therapy device |
US7892196B2 (en) | 2001-11-16 | 2011-02-22 | Fresenius Medical Care Holdings, Inc. | Wearable continuous renal replacement therapy device |
US20080058696A1 (en) * | 2001-11-16 | 2008-03-06 | National Quality Care, Inc | Wearable continuous renal replacement therapy device |
US20100094193A1 (en) * | 2001-11-16 | 2010-04-15 | National Quality Care, Inc. | Wearable ultrafiltration device |
US20070038191A1 (en) * | 2003-01-15 | 2007-02-15 | Burbank Jeffrey H | Waste balancing for extracorporeal blood treatment systems |
US8235931B2 (en) | 2003-01-15 | 2012-08-07 | Nxstage Medical, Inc. | Waste balancing for extracorporeal blood treatment systems |
US7686778B2 (en) | 2003-01-15 | 2010-03-30 | Nxstage Medical, Inc. | Waste balancing for extracorporeal blood treatment systems |
US20070066928A1 (en) * | 2005-09-22 | 2007-03-22 | Jean-Michel Lannoy | Automation and optimization of CRRT treatment using regional citrate anticoagulation |
US8372025B2 (en) | 2005-09-22 | 2013-02-12 | Baxter International Inc. | Automation and optimization of CRRT treatment using regional citrate anticoagulation |
US9022966B2 (en) | 2005-09-22 | 2015-05-05 | Nikkiso Co., Ltd. | Regional citrate anticoagulation |
JP2009509584A (en) * | 2005-09-22 | 2009-03-12 | エドワーズ ライフサイエンシーズ コーポレイション | Automation and optimization of CRRT therapy using local citrate anticoagulant |
WO2007038347A1 (en) * | 2005-09-22 | 2007-04-05 | Edwards Lifesciences Corporation | Automation and optimization of crrt treatment using regional citrate anticoagulation |
EP2324871B1 (en) | 2005-11-22 | 2016-06-22 | Nikkiso Co., Ltd. | Citrate anticoagulation system for extracorporeal blood treatments |
US8133194B2 (en) | 2006-02-22 | 2012-03-13 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
WO2007101064A3 (en) * | 2006-02-22 | 2008-11-06 | Ford Henry Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
US8945036B2 (en) | 2006-02-22 | 2015-02-03 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
EP1998826A2 (en) * | 2006-02-22 | 2008-12-10 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
US8211048B2 (en) * | 2006-02-22 | 2012-07-03 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
US20090221948A1 (en) * | 2006-02-22 | 2009-09-03 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
JP2009527343A (en) * | 2006-02-22 | 2009-07-30 | ヘンリー フォード ヘルス システム | Topical citrate anticoagulant delivery system and method to extracorporeal blood circuit |
WO2007101064A2 (en) * | 2006-02-22 | 2007-09-07 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
EP1998826A4 (en) * | 2006-02-22 | 2012-02-08 | Ford Henry Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
US20080015487A1 (en) * | 2006-02-22 | 2008-01-17 | Henry Ford Health System | System and Method for Delivery of Regional Citrate Anticoagulation to Extracorporeal Blood Circuits |
AT505690B1 (en) * | 2007-08-31 | 2012-09-15 | Zentrum Fuer Biomedizinische Technologie Der Donau Uni Krems | METHOD OF DETERMINING ION CONCENTRATION IN CITRATE ANTICOAGULATED EXTRACORPORAL BLOOD CLEANING |
US10456517B2 (en) | 2007-09-05 | 2019-10-29 | Gambro Lundia Ab | Infusion site for improved mixing of fluids |
EP3797806A1 (en) * | 2007-09-05 | 2021-03-31 | Gambro Lundia AB | Infusion site for improved mixing of fluids |
US11738132B2 (en) | 2007-09-05 | 2023-08-29 | Gambro Lundia Ab | Infusion site for improved mixing of fluids |
EP3042673A1 (en) * | 2007-09-05 | 2016-07-13 | Gambro Lundia AB | Infusion site for improved mixing of fluids |
US20140353251A1 (en) * | 2009-06-17 | 2014-12-04 | Fresenius Medical Care Holdings, Inc. | Methods of Regional Citrate Anticoagulation Dialysis |
US10525186B2 (en) * | 2009-06-17 | 2020-01-07 | Fresenius Medical Care Holdings, Inc. | Methods of regional citrate anticoagulation dialysis |
US11118162B2 (en) | 2010-10-15 | 2021-09-14 | Seastar Medical, Inc. | Cytopheresis cartridges and use thereof |
US11866730B2 (en) | 2010-10-15 | 2024-01-09 | Seastar Medical, Inc. | Cytopheresis cartridges and use thereof |
JP2012135499A (en) * | 2010-12-27 | 2012-07-19 | Asahi Kasei Medical Co Ltd | Blood purification system |
EP2526981A1 (en) * | 2011-05-25 | 2012-11-28 | Bellco S.r.l. | Infusion assembly of a dialysis machine |
US10695482B2 (en) | 2011-10-14 | 2020-06-30 | Seastar Medical, Inc. | Cartridge and method for increasing myocardial function |
US10722637B2 (en) | 2012-01-09 | 2020-07-28 | Seastar Medical, Inc. | Cartridge and method for increasing myocardial function |
US11439739B2 (en) | 2012-01-09 | 2022-09-13 | Seastar Medical, Inc. | Cartridge and method for increasing myocardial function |
KR102105431B1 (en) * | 2012-03-21 | 2020-04-29 | 감브로 룬디아 아베 | Treatment solution delivery in an extracorporeal blood treatment apparatus |
US11020517B2 (en) | 2012-03-21 | 2021-06-01 | Gambro Lundia Ab | Treatment solution delivery in an extracorporeal blood treatment apparatus |
KR20140137443A (en) * | 2012-03-21 | 2014-12-02 | 감브로 룬디아 아베 | Treatment solution delivery in an extracorporeal blood treatment apparatus |
US10245364B2 (en) | 2012-04-16 | 2019-04-02 | Fresenius Medical Care Deutschland Gmbh | Safety apparatus for extracorporeal blood treatment |
WO2013156435A1 (en) | 2012-04-16 | 2013-10-24 | Zentrum Für Biomedizinische Technologie Der Donau-Universität Krems | Safety apparatus for extracorporeal blood treatment |
EP2653178A1 (en) | 2012-04-16 | 2013-10-23 | Zentrum für biomedizinische Technologie der Donau- Universität Krems | Safety device for extracorporeal blood treatment |
US20160121035A1 (en) * | 2014-10-31 | 2016-05-05 | B. Braun Avitum Ag | System and method for flexible citrate anticoagulation during extracorporeal blood treatment using feed-forward control |
US10953146B2 (en) * | 2014-10-31 | 2021-03-23 | B. Braun Avitum Ag | System and method for flexible citrate anticoagulation during extracorporeal blood treatment using feed-forward control |
CN105561416A (en) * | 2014-10-31 | 2016-05-11 | B·布莱恩·阿维图姆股份公司 | System for extracorporeal blood treatment |
Also Published As
Publication number | Publication date |
---|---|
US7351218B2 (en) | 2008-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7351218B2 (en) | Device and process for extracorporeal treatment by citrate anticoagulant | |
KR101244119B1 (en) | Method of operating a dialysis machine | |
US6911007B2 (en) | Method for determining concentration; a dialyser | |
US20130338560A1 (en) | Method and apparatus for determining access flow | |
US20080004225A1 (en) | New dialysis method | |
JP7210471B2 (en) | Method for operating a blood processing device, control unit and processing device for carrying out the method | |
JP7143287B2 (en) | A method for removing blood from an extracorporeal blood circuit after completing a blood treatment session, a control and regulation unit for carrying out the method, and a processing device | |
EP1430920B1 (en) | Device for extracorporeal blood treatment by citrate anticoagulation | |
US10646635B2 (en) | Method and apparatuses for preparing an extracorporeal blood circuit for the treatment of blood | |
US20040020852A1 (en) | Method and apparatus for calcium profiling in dialysis | |
Golper et al. | Continuous venovenous hemofiltration for acute renal failure in the intensive care setting: Technical considerations | |
WO2021059817A1 (en) | Blood purification device | |
MXPA01007006A (en) | New dialysis method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GAMBRO LUNDIA AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HOSPAL INTERNATIONAL MARKETING MANAGEMENT SNC;REEL/FRAME:014832/0624 Effective date: 20021219 Owner name: HOSPAL INTERNATIONAL MARKETING MANAGEMENT SNC, FRA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BENE, BERNARD;REEL/FRAME:014832/0626 Effective date: 20021219 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
AS | Assignment |
Owner name: CITICORP TRUSTEE COMPANY LIMITED, UNITED KINGDOM Free format text: IP SECURITY AGREEMENT SUPPLEMENT;ASSIGNOR:GAMBRO LUNDIA AB;REEL/FRAME:022714/0702 Effective date: 20090331 Owner name: CITICORP TRUSTEE COMPANY LIMITED,UNITED KINGDOM Free format text: IP SECURITY AGREEMENT SUPPLEMENT;ASSIGNOR:GAMBRO LUNDIA AB;REEL/FRAME:022714/0702 Effective date: 20090331 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: GAMBRO LUNDIA AB, COLORADO Free format text: RELEASE OF SECURITY INTEREST IN PATENTS;ASSIGNOR:CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT;REEL/FRAME:027456/0050 Effective date: 20111207 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |